BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04.03.2020

An Open Letter to Patients and Their Families from BridgeBio Pharma CEO Neil Kumar

03.19.2020

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

03.12.2020

BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

03.04.2020

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

03.04.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03.03.2020

BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

03.02.2020

BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors

02.24.2020

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

02.21.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02.05.2020

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

01.13.2020

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

01.10.2020

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People with High Frequency Basal Cell Carcinoma

01.08.2020

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

01.06.2020

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

12.19.2019

BridgeBio Pharma’s Origin Biosciences Enters Partnership with Medison To Commercialize BBP-870 In Israel for MoCD Type A

12.18.2019

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

12.16.2019

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

12.09.2019

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.05.2019

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A

12.03.2019

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn and Twitter to keep up with all the latest news.

Links to an external site